

VioQuest Pharmaceuticals, Inc.  
Form 4  
June 17, 2008

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2005  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
LENZ BRIAN

2. Issuer Name and Ticker or Trading Symbol  
VioQuest Pharmaceuticals, Inc.  
[VQPH]

5. Relationship of Reporting Person(s) to Issuer  
  
(Check all applicable)

(Last) (First) (Middle)  
180 MT. AIRY ROAD, SUITE 102  
  
(Street)

3. Date of Earliest Transaction  
(Month/Day/Year)  
06/13/2008

\_\_\_\_ Director \_\_\_\_\_ 10% Owner  
 Officer (give title below) \_\_\_\_\_ Other (specify below)  
CFO and Treasurer

BASKING RIDGE, NJ 07920

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
				(A) or (D) Price			
Common Stock					1,500 <sup>(1)</sup>	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474 (9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

Edgar Filing: VioQuest Pharmaceuticals, Inc. - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title
Warrant	\$ 4 <sup>(1)</sup>							06/29/2007	06/29/2012	Common Stock, \$.001 par value
Warrant	\$ 1 <sup>(1)</sup>							04/09/2008	04/09/2013	Common Stock
Series B Convertible Preferred Stock	\$ 3.8 <sup>(1)</sup>							03/14/2008	<sup>(8)</sup>	Series A Convertible Preferred Stock
Series A Convertible Preferred Stock	\$ 0.6 <sup>(1)</sup>							04/09/2008	<sup>(8)</sup>	Common Stock
Stock Options	\$ 16.7 <sup>(1)</sup>	06/13/2008		D <sup>(2)</sup>			1,500 <sup>(1)</sup>	<sup>(2)</sup>	10/06/2013	Common Stock
Stock Options	\$ 0.54	06/13/2008		A <sup>(2)</sup>		1,500		<sup>(2)</sup>	10/06/2013	Common Stock
Stock Options	\$ 14 <sup>(1)</sup>	06/13/2008		D <sup>(3)</sup>			2,500 <sup>(1)</sup>	<sup>(3)</sup>	04/19/2014	Common Stock
Stock Options	\$ 0.54	06/13/2008		A <sup>(3)</sup>		2,500		<sup>(3)</sup>	04/19/2014	Common Stock
Stock Options	\$ 10.8 <sup>(1)</sup>	06/13/2008		D <sup>(4)</sup>			6,000 <sup>(1)</sup>	<sup>(4)</sup>	01/24/2015	Common Stock
Stock Options	\$ 0.54	06/13/2008		A <sup>(4)</sup>		6,000		<sup>(4)</sup>	01/24/2015	Common Stock
Stock Options	\$ 10.3 <sup>(1)</sup>	06/13/2008		D <sup>(5)</sup>			10,000 <sup>(1)</sup>	<sup>(5)</sup>	11/29/2015	Common Stock
Stock Options	\$ 0.54	06/13/2008		A <sup>(5)</sup>		10,000		<sup>(5)</sup>	11/29/2015	Common Stock
Stock Options	\$ 8.5 <sup>(1)</sup>	06/13/2008		D <sup>(6)</sup>			10,000 <sup>(1)</sup>	<sup>(6)</sup>	03/31/2016	Common Stock
Stock Options	\$ 0.54	06/13/2008		A <sup>(6)</sup>		10,000		<sup>(6)</sup>	03/31/2016	Common Stock
Stock Options	\$ 5.5 <sup>(1)</sup>	06/13/2008		D <sup>(7)</sup>			10,000 <sup>(1)</sup>	<sup>(7)</sup>	05/11/2007	Common Stock

Edgar Filing: VioQuest Pharmaceuticals, Inc. - Form 4

Stock Options	\$ 0.54	06/13/2008	A <sup>(7)</sup>	10,000	<sup>(7)</sup>	05/11/2017	Common Stock
Stock Options	\$ 1.2 <sup>(1)</sup>	06/13/2008	D <sup>(9)</sup>	8,000 <sup>(1)</sup>	<sup>(9)</sup>	02/28/2018	Common Stock
Stock Options	\$ 0.54	06/13/2008	A <sup>(9)</sup>	8,000	<sup>(9)</sup>	02/28/2018	Common Stock
Stock Options	\$ 0.54	06/13/2008	A	80,000	<sup>(10)</sup>	06/13/2018	Common Stock

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
LENZ BRIAN 180 MT. AIRY ROAD, SUITE 102 BASKING RIDGE, NJ 07920			CFO and Treasurer	

## Signatures

/s/ Brian Lenz                      06/16/2008

    Signature of  
Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Adjusted to reflect a 1-for-10 reverse stock split effective on 4/25/2008.
- (2) This transaction involves an amendment to an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on 10/6/2003 and is fully vested.
- (3) This transaction involves an amendment to an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on 4/19/2004 and is fully vested.
- (4) This transaction involves an amendment to an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on 1/24/2005 and is fully vested.
- (5) This transaction involves an amendment to an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on 11/29/2005 and provides for vesting in three annual installments beginning on 11/29/06.
- (6) This transaction involves an amendment to an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on 3/31/2006 and provides for vesting in three annual installments beginning on 3/31/07.
- (7) This transaction involves an amendment to an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on 5/11/2007 and provides for vesting in three annual installments beginning on 5/11/2008.
- (8) No expiration date.
- (9) This transaction involves an amendment to an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on 2/28/2008 and provides for vesting in three annual installments beginning on 2/28/09 and is subject to acceleration under certain circumstances.
- (10) Option vests in three annual installments beginning on 6/13/08.

## Edgar Filing: VioQuest Pharmaceuticals, Inc. - Form 4

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.  
Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.